[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-thromboembolic-pulmonary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-thromboembolic-pulmonary-hypertension":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,47,76,101,131,153,179,203,229,250,276,302,327,356,381,406,425],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100538135","frailty-physical-capacity-and-lung-function-in-postoperative-pulmonary-endarterectomy-patients-100538135",false,"NCT06286891","Frailty, Physical Capacity and Lung Function in Postoperative Pulmonary Endarterectomy Patients","Evaluation of Frailty, Physical Capacity and Lung Function in Postoperative Pulmonary Endarterectomy Patients: an Observational and Prospective Clinical Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both genders\n* Elective pulmonary endarterectomy surgery\n* Absence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the preoperative period.\n\nExclusion Criteria:\n\n* Reoperation for any reason\n* Presence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the postoperative period.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","The goal of this observational and prospective study is to investigate changes in physical performance, lung function, respiratory and peripheral muscle strength in patients during the postoperative period following pulmonary endarterectomy (PET).",[24,25,26],"Chronic Thromboembolic Pulmonary Hypertension","Physical Disability","Fragility",[28,29,30,31,32,33],"Pulmonary Endarterectomy Surgery","Six-minute walk test","Short Physical Performance Battery","One-minute sit-to-stand test","Muscular strength","Spirometry","RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2024-02-29",{"date":42,"type":20},"2026-11-30",{"name":44,"class":45},"University of Sao Paulo General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100519060","phase-2-129xe-mri-cardiopulmonary-100519060","NCT06038630","129Xe MRI Cardiopulmonary","129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function","Inclusion Criteria for Healthy Volunteers:\n\n(Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)\n\n1. Outpatients of either gender, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol (Consent must be given before any study procedures are performed.)\n3. Subject has no diagnosed pulmonary conditions\n4. Subject has not smoked in the previous 5 years\n5. Smoking history, if any, is less than or equal to 5 pack-years\n6. No history of using other inhaled products more than 1\u002Fweek for \\> 1 year\n\nInclusion Criteria for Transfusion and Phlebotomy Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following:\n\n1. Patients who are scheduled to receive a red cell transfusion for anemia.\n2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia\n3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)\n\nInclusion Criteria for Oxygen Administration Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):\n\n1. Interstitial Lung Disease or Dyspnea\n\n   * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\n   OR\n3. Healthy Volunteer (criteria noted above)\n\nInclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (Acute or Chronic)\n\n1. Acute Pulmonary Embolism\n\n   * Patients presenting with acute PE 24-48hrs post-admission\n   * Willing to return after 3-6 months of anti-coagulation therapy\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\nExclusion Criteria for All subjects:\n\nSubjects presenting with any of the following will not be included in the trial:\n\n1. MRI is contraindicated based on responses to MRI screening questionnaire\n2. Subject is pregnant or lactating\n3. Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI\n5. Subject has history of any known ventricular cardiac arrhythmia\n6. Subject has history of cardiac arrest within the last year\n7. Subject does not fit into 129Xe vest coil used for MRI\n8. Subject cannot hold his\u002Fher breath for 10 seconds\n9. Subject deemed unlikely to be able to comply with instructions during imaging\n10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",true,{"count":56,"type":20},125,"INTERVENTIONAL",[59],"PHASE2","The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.",[62,24,63,64,65,66],"Interstitial Lung Disease","Acute Pulmonary Embolism","Anemia","Polycythemia","Dyspnea","2026-02-02",{"date":69,"type":38},"2026-02-04",{"date":71,"type":38},"2024-01-12",{"date":73,"type":20},"2028-06-30",{"name":75,"class":45},"Bastiaan Driehuys",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":21,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100613915","cardiac-self-efficacy-in-patients-with-chronic-thromboembolic-pulmonary-hypertension-100613915","NCT07272798","Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension","CTEPH3","Inclusion Criteria:\n\n* all patients undergoing pulmonary thromboendarterectomy for CTEPH\n* Able to read and understand the informed consent form and study questionnaires\n\nExclusion Criteria:\n\n* Patients undergoing Balloon Pulmonary Angioplasty (BPA) or receiving only medical therapy (as the focus is on the surgical cohort).\n* Emergency or salvage PEA procedures (to ensure stable baseline assessment).\n* Inability to complete the questionnaires due to severe cognitive impairment, psychiatric illness, or language barrier.",{"count":84,"type":20},10,"6 Months","This study aims to analyze the effect of Pulmonary Endarterectomy (PEA) on patients' self-confidence in managing their chronic illness.\n\nPatients' confidence (or self-efficacy) will be measured using the following questionnaires: 10-item Perceived Efficacy in Patient-Physician Interaction Scale (PEPPI), Self-Efficacy for Managing Chronic Diseases 6-item Scale (SEMCD-6), Sullivan's cardiac self-efficacy scale 13-items (SCSES). The association between improved confidence and better physical results will be analyzed, such as being able to walk longer (6 mint walk test (6-Minute Walk Test)).\n\nUltimately, this study will help understanding the psychological side of recovery and might lead to better support programs to help patients feel more capable and live better lives after their operation.",[24],[89,90,91],"Chronic thromboembolic pulmonary hypertension","self efficacy","functional capacity","2025-12-09",{"date":94,"type":38},"2025-12-17",{"date":96,"type":38},"2025-11-20",{"date":98,"type":20},"2026-11-20",{"name":100,"class":45},"Damascus University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":46},"100612476","registry-of-patients-with-chronic-thromboembolic-pulmonary-hypertension-100612476","NCT07254078","Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension","Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Russia: Determinants of Long-term Outcomes in Real Clinical Practice","POLET","Inclusion Criteria:\n\n* Presence of a confirmed diagnosis of CTEPH\n\nExclusion Criteria:\n\n* Presence of pulmonary hypertension of a different etiology than CTEPH",{"count":110,"type":20},500,"10 Years","The goal of this observational study is to gather information on background, medical history, symptoms and physical condition, treatment options of people with chronic thromboembolic pulmonary hypertension in real clinical practice in Russia.\n\nThe main question it aims to answer is:\n\nWhich factors most influence the prognosis of participants?",[24],[115,116,117,118,119,120],"CTEPH","registry","PEA","BPA","PAH-specific therapy","survival","2025-12-04",{"date":123,"type":38},"2025-12-12",{"date":125,"type":38},"2025-05-01",{"date":127,"type":20},"2035-05-01",{"name":129,"class":130},"Irina E. Chazova","OTHER_GOV",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100522381","chronic-thromboembolic-pulmonary-hypertension-after-pulmonary-embolism-100522381","NCT06081881","Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism","Predictors for Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism Episode","Inclusion Criteria:\n\nAny patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1,\n\nExclusion Criteria:\n\nSecondary causes for pulmonary hypertension Severe kidney injury(eGFR\\>30 mg\u002Fdl\u002F1.7m2) Hepatic affection Contraindication to anti-coagulation","80 Years",{"count":140,"type":20},100,"to detect the incidence of CTEPH patients.\n\nPrimary outcome To predict CETHP in symptomatic patients after pulmonary embolism episode.\n\nSecondary outcome:\n\nOn Echocardiography revealed RV dysfunction which are peak TR Velocity , the RV\u002FLV basal diameter ratio, flattening of the IVS, RV acceleration time and\u002For midsystolic notching, IVC diameter with decreased inspiratory collapse and RA area.",[24],[115],"2025-11-27",{"date":146,"type":38},"2025-12-01",{"date":148,"type":38},"2025-01-01",{"date":150,"type":20},"2026-12-01",{"name":152,"class":45},"Ester Ashraf Faried Beshay",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100465384","proteomic-pattern-associated-with-the-diagnosis-of-chronic-thromboembolic-pulmonary-hypertension-100465384","NCT05340023","Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension","Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension : PROTEO-CTEPH Study.","PROTEO-CTEPH","Inclusion Criteria:\n\n* Patient with a suspicion of Chronic thromboembolic pulmonary hypertension (CTEPH) with a combination of a perfusion lung scan and transthoracic perfusion scan and transthoracic echocardiography compatible with the diagnosis (according to French recommendations)\n* Patients who require a right heart catheterization.\n* Patient affiliated or entitled to a social security plan\n* Patient having received informed information about the study informed about the study\n\nExclusion Criteria:\n\n* Patient with a normal perfusion lung scan\n* Person under legal guardianship",{"count":162,"type":20},120,"Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) is a rare but severe complication of pulmonary embolism (PE). CTEPH is evoked in patients with persistent dyspnea. According to international guidelines, symptomatic patients with perfusion defects on lung scan and Pulmonary Hypertension (PH)-likely transthoracic echo (TTE) must be evaluated in Pulmonary Hypertension (PH)-centers with right heart catheterism, to confirm or rule out the presence of precapillary Pulmonary Hypertension (PH), and precise the group of Pulmonary Hypertension (PH).",[24],[166,167,168,169],"Pulmonary hypertension;","chronic thromboembolic pulmonary hypertension","pulmonary embolism","proteomic pattern","2025-11-21",{"date":172,"type":38},"2025-11-24",{"date":174,"type":38},"2022-11-09",{"date":176,"type":20},"2027-05",{"name":178,"class":45},"Centre Hospitalier Universitaire de Saint Etienne",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":111,"studyType":21,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100367979","pulmonary-hypertension-association-registry-100367979","NCT04071327","Pulmonary Hypertension Association Registry","PHAR","Inclusion Criteria:\n\n* All age groups\n* Written informed consent\n* Pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or pediatric PH due to developmental lung disease\n* Within 6 months of first outpatient visit at a PH Care Center\n\nExclusion Criteria:\n\n* Diagnosis of WSPH Group 2 pulmonary hypertension\n* Diagnosis of WSPH Group 3 pulmonary hypertension, except PH due to developmental lung disease\n* Diagnosis of WSPH Group 5 pulmonary hypertension","0 Years",{"count":188,"type":20},3000,"The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S.\n\nPHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes.\n\nPHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.",[191,24,192],"Pulmonary Arterial Hypertension","Pulmonary Hypertension","2025-11-13",{"date":195,"type":38},"2025-11-14",{"date":197,"type":38},"2015-10",{"date":199,"type":20},"2025-12",{"name":201,"class":45},"Pulmonary Hypertension Association, Inc.",52,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":85,"studyType":21,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":46},"100424568","pulmonary-hypertension-biorepository-and-registry-100424568","NCT04808596","Pulmonary Hypertension Biorepository and Registry","PHBR","Inclusion Criteria:\n\n1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)\n2. The participant has a diagnosis of pulmonary hypertension confirmed by right heart catheterization\n3. Patient is ≥ 18 years of age or older\n\nExclusion Criteria:\n\n1. Participant declines to participate (living patients only)\n2. Participant is unable to provide informed consent (living patients only)",{"count":211,"type":20},300,"Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.",[192,191,214,215,216,217,218,219,24],"Pulmonary Hypertension Due to Left Heart Disease","Pulmonary Hypertension, Primary","Pulmonary Hypertension Due to Lung Diseases and Hypoxia","Pulmonary Hypertension, Primary, 4","Pulmonary Hypertension, Primary, 2","Pulmonary Hypertension, Primary, 3","2025-07-29",{"date":222,"type":38},"2025-08-01",{"date":224,"type":38},"2020-08-10",{"date":226,"type":20},"2027-07-31",{"name":228,"class":45},"University of Kansas Medical Center",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":237,"studyType":21,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":46},"100504070","chronic-thromboembolic-disease-registry-100504070","NCT05843500","Chronic Thromboembolic Disease Registry","Chronic Thromboembolic Disease: A Prospective Registry","Inclusion Criteria:\n\n* Patients referred with CTED and\u002For CTEPH defined as:\n\n  1. Mean pulmonary arterial pressure (mPAP) \\> 20 mmHg at rest with pulmonary vascular resistance (PVR) \\> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH)\n  2. Radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram\n  3. Post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension\n* Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Main cause of PH other than World Health Organization (WHO) group 4 (CTEPH)\n* Patient's refusal to participate in clinical research and\u002For receive intervention",{"count":140,"type":20},"5 Years","The goal of this patient registry is to learn about the natural history in patients with chronic thromboembolic disease (CTD) and\u002For chronic thromboembolic pulmonary hypertension (CTEPH). The main question\\[s\\] it aims to answer are:\n\n* Long-term outcome after various types of treatment, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy\n* Effect of treatment on patient's quality of life and exercise tolerance Participants will be followed longitudinally to assess their health outcomes and quality of life via chart review and health quality surveys.",[24,240],"Chronic Thromboembolic Disease","2025-06-09",{"date":243,"type":38},"2025-06-12",{"date":245,"type":38},"2023-08-01",{"date":247,"type":20},"2028-07-01",{"name":249,"class":45},"University of California, San Francisco",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":57,"phases":260,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":46},"100571056","phase-4-switching-of-sildenafil-to-riociguat-in-cteph-patients-100571056","NCT06715280","Switching of Sildenafil to Riociguat in CTEPH Patients","Switching Sildenafil to Riociguat in Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty","S2R","Inclusion Criteria:\n\n1. Patients with established diagnosis of CTEPH who are symptomatic after Balloon pulmonary angioplasty (BPA)\n2. Patients who are on stable maximally tolerated dose of sildenafil for at least 6 weeks as monotherapy, or in combination with other pulmonary hypertension specific therapies\n3. WHO functional class III at screening\n4. Stable dose of diuretics (if used) for at least 30 days at screening\n5. No recent hospitalisation due to pulmonary hypertension or heart failure for at least 30 days\n\nExclusion Criteria:\n\n1. Previous treatment with riociguat other sGCs, or documented severe drug reaction or intolerance to sGCs\n2. Use of nitrates or nitric oxide donors (eg, nitroglycerin, amyl nitrite, isosorbide dinitrate etc) by any administration routes within 30 days of screening\n3. Pregnant women or breast-feeding women, or women with childbearing potential not using of combination of two effective contraception methods throughout study\n4. Renal impairment with glomerular filtration rate \\\u003C15mL \u002Fmin\n5. Child-Pugh C hepatic impairment",{"count":259,"type":20},30,[261],"PHASE4","This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.",[24],[115,118,265,266],"Riociguat","Sildenafil","2025-05-23",{"date":269,"type":38},"2025-05-29",{"date":271,"type":38},"2024-07-25",{"date":273,"type":20},"2027-01-22",{"name":275,"class":45},"Chinese University of Hong Kong",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":57,"phases":286,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100586965","phase-3-riociguat-discontinue-effects-on-right-heart-in-cteph-red-heart-100586965","NCT06922240","Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)","Effect of Discontinuation of Riociguat on Right Heart Function in Patients With CTEPH After Combination Therapy","RED-HEART","Inclusion Criteria:\n\n* Age ≥18 years old\n* CTEPH was diagnosed and one of the following three factors was met: Pulmonary endarterectomy was technically impossible; Pulmonary endarterectomy is technically feasible, but the risk-benefit ratio is poor; Residual\u002Frecurrent pulmonary hypertension after pulmonary endarterectomy\n* Subjects had been treated with BPA and had received a stable dose of riociguat for ≥12 weeks\n* mPAP \\\u003C 30mmHg\n* Male subjects and female subjects of reproductive age are required to use effective contraception for at least 28 days after signing the informed consent form. Male subjects are not allowed to donate sperm and female subjects are not allowed to breastfeed.\n* Subjects voluntarily sign written informed consent\n\nExclusion Criteria:\n\n* Severe hepatic and renal insufficiency (Child-Pugh Grade C\u002Fcreatinine clearance \\\u003C 30ml\u002Fmin·1.73m²)\n* The presence of severe infectious disease or severe bleeding tendency\n* Combined with pulmonary hypertension of other types than CTEPH\n* Other pulmonary hypertension targeting drugs are being used\n* The expected survival time with cancer or other diseases is less than 6 months\n* Pregnancy, lactation\n* Subjects are currently participating in an interventional clinical trial\n* In the investigator's judgment, a subject's medical abnormality, physical condition, or medical history may affect his or her ability to participate in or complete the study",{"count":285,"type":20},68,[287],"PHASE3","Riociguat and balloon pulmonary angioplasty (BPA) are established standard-of-care interventions for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) with comparable evidence levels. However, the optimal combined treatment strategy remains unclear. Specifically, there is no consensus on whether riociguat should be continued long-term after achieving hemodynamic stability with BPA. Additionally, the long-term effects of riociguat discontinuation on right ventricular (RV) structure and function remain poorly characterized, particularly due to the lack of comprehensive noninvasive evaluations integrating cardiac magnetic resonance (CMR) and echocardiography. This prospective study aims to determine the hemodynamic impact of riociguat discontinuation in inoperable CTEPH patients who have achieved BPA treatment endpoints using right heart catheterization (RHC). Evaluate RV remodeling and functional changes after riociguat cessation through multimodal noninvasive imaging (CMR, echocardiography). Assess safety outcomes and identify potential rebound pulmonary hypertension or decompensated RV dysfunction associated with riociguat withdrawal.",[24],[24,265,291],"Right heart function","2025-04-27",{"date":294,"type":38},"2025-04-30",{"date":296,"type":38},"2025-03-21",{"date":298,"type":20},"2027-10-31",{"name":300,"class":45},"Suqiao Yang",3,{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":54,"sex":16,"minAge":237,"maxAge":309,"enrollmentInfo":310,"targetDuration":237,"studyType":21,"phases":4,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":46},"100213915","the-application-of-cardiopulmonary-exercise-testing-in-assessment-outcome-of-patients-with-pulmonary-hypertension-100213915","NCT02061787","the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension","CPETPH","Inclusion Criteria:\n\n* pulmonary arterial hypertension;( WHO1)\n* chronic thromboembolic pulmonary hypertension;\n* pulmonary arterial hypertension due to other cause;\n\nExclusion Criteria:\n\n* massive hemoptysis;\n* unable to accomplish cardiopulmonary exercise testing due to neuromuscular disorders;\n* recent recurrent syncope;\n* pulmonary hypertension due to hypoxia;\n* pulmonary hypertension due to left heart diseases.","100 Years",{"count":311,"type":20},4000,"cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment",[192,24,314],"Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)",[24,191,316,317],"balloon pulmonary angioplasty","cardiopulmonary exercise test","2024-09-09",{"date":320,"type":38},"2024-09-19",{"date":322,"type":38},"2010-09",{"date":324,"type":20},"2030-09-08",{"name":326,"class":45},"Chinese Pulmonary Vascular Disease Research Group",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":16,"minAge":334,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":46},"100556543","chinese-pe-multimodality-imaging-artificial-intelligence-study-100556543","NCT06526468","Chinese PE Multimodality Imaging Artificial Intelligence Study","CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study","Inclusion Criteria:\n\n* 14 Years and older\n* Patients suspected of PE\n\nExclusion Criteria:\n\n* Pregnant women\n* Refuse to follow up\n* Incomplete or discontinued imaging scans\n* Insufficient quality of image data to allow for analysis","14 Years",{"count":336,"type":20},1500,"The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.",[339,24,340],"Pulmonary Embolism","Chronic Thromboembolic Pulmonary Disease",[342,343,344,345,346],"imaging","early diagnosis","differential diagnosis","risk stratification","prognosis assessment","2024-08-27",{"date":349,"type":38},"2024-08-28",{"date":351,"type":38},"2010-09-01",{"date":353,"type":20},"2028-09-01",{"name":355,"class":45},"China-Japan Friendship Hospital",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":57,"phases":367,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100447717","bpa-vs-pea-in-cteph-100447717","NCT05110066","BPA vs. PEA in CTEPH","Balloon Pulmonary anGiOplasty Versus Pulmonary Endarterectomy in Patients With Chronic ThromboEmbolic Pulmonary Hypertension: a Non-inferiority Randomized Trial","GO-CTEPH","Inclusion Criteria:\n\n* Diagnosed with chronic thromboembolic pulmonary hypertension according to current European society of cardiology\u002FEuropean Respiratory Society guidelines and eligible for both pulmonary endarterectomy and ballon pulmonary angioplasty by decision at the local multidisciplinary team conference and central adjudication committee\n* Written informed consent from the patient\n* Patient age \\>17 and \\\u003C80 years\n* Able to understand and follow instructions and to participate in the entire study period\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C12 months\n* Co morbidities evaluated at the multidisciplinary team conference, that contributes significantly to the patients pulmonary hypertension\n* Not possible to perform balloon pulmonary angioplasty or pulmonary endarterectomy within 4 months after randomization.\n* Evaluated at multidisciplinary team conference that changes in pulmonary artery hypertension targeted therapy between baseline and 4 months follow-up is inevitable\\*\n* Known pregnancy or positive urine Human chorionic gonadotropin screening test in fertile women\n* Previous balloon pulmonary angioplasty or pulmonary endarterectomy","79 Years",{"count":366,"type":20},139,[368],"NA","Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-threatening progressive disease that evolves from unresolved pulmonary embolism. Gold standard treatment for CTEPH is pulmonary endarterectomy (PEA) performed by skilled cardio-thoracic surgeons.\n\nSome patients may not be surgical candidates due to co-morbidities or because the vascular lesions are too distal making them technically inoperable. In these patients, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment. In a subgroup of patients, the distribution of vascular lesions makes it possible to perform either BPA or PEA. There has never been a head-to head comparison of BPA with PEA. The aim of this study is therefore, to evaluate if BPA is non-inferior to PEA in patients with (CTEPH) who are eligible for both treatments.",[24],"2024-04-26",{"date":373,"type":38},"2024-04-29",{"date":375,"type":38},"2024-04-01",{"date":377,"type":20},"2028-04-01",{"name":379,"class":45},"University of Aarhus",2,{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":334,"maxAge":4,"enrollmentInfo":388,"targetDuration":389,"studyType":21,"phases":4,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":46},"100463159","change-a-multi-center-chronic-thromboembolic-pulmonary-hypertension-cteph-database-in-china-100463159","NCT05311072","Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China","A Chinese Real-world Study to Investigate the Management Pattern and Outcomes of Chronic Thromboembolic Pulmonary Hypertension (CHANGE Study)","Inclusion Criteria:\n\n1. Patients must be diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH)\n2. Patients must be willing to provide informed consent\n3. Patients must meet the following criteria for CTEPH:\n\na mean pulmonary artery pressures (mPAP) ≥20 mmHg combined with a pulmonary vascular resistance (PVR) ≥ 3 WU and pulmonary arterial wedge pressure (PAWP)≤ 15 mmHg documented at right heart catheterization with radiographic evidence of organized thrombi involving the pulmonary arteries after 3 months of effective anticoagulation.\n\nExclusion Criteria:\n\n1. Main cause of PH other than CTEPH\n2. Participation in a therapeutic clinical trial with an unknown drug;\n3. Withdrawal or lack of informed consent.",{"count":336,"type":20},"3 Years","The Change Database is a prospective, observational multi-center disease registry, which will collect data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) in China. It aims to illustrate the epidemiology, management and long-term outcomes of CTEPH.",[24],[24,393,394,395,396,316,397],"epidemiology","diagnosis","treatment","prognosis","pulmonary endarterectomy","2024-01-20",{"date":400,"type":38},"2024-01-23",{"date":402,"type":38},"2015-10-01",{"date":404,"type":20},"2027-12-31",{"name":355,"class":45},{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":412,"targetDuration":414,"studyType":21,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":380},"100378384","safety-and-efficacy-of-balloon-pulmonary-angioplasty-in-china-100378384","NCT04206852","Safety and Efficacy of Balloon Pulmonary Angioplasty in China","Inclusion Criteria:\n\n1. diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP \\\u003C 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines\n2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH\n3. Not amenable to pulmonary endarterectomy\n4. Willing to provide informed consent\n\nExclusion Criteria:\n\n1. Patients unwilling or unable to provide written consent for participation in the study.\n2. Impossible to follow up.",{"count":413,"type":20},200,"4 Years","Balloon pulmonary angioplasty (BPA) is a potential treatment for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH).\n\nThe aim of this study was to evaluate the safety and efficacy of BPA in CTEPH patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA.",[24],"2023-12-14",{"date":419,"type":38},"2023-12-20",{"date":421,"type":38},"2018-05-11",{"date":423,"type":20},"2028-05-11",{"name":326,"class":45},{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":432,"maxAge":4,"enrollmentInfo":433,"targetDuration":237,"studyType":21,"phases":4,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":46},"100359413","database-of-pulmonary-hypertesion-in-polish-population---bnp-pl-100359413","NCT03959748","DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL","BNP-PL","Inclusion Criteria:\n\nPatients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension diagnosed after 1st March 2018 (incident cases) who:\n\n* are aged \\> 3 months at the time of enrollment\n* fulfill the following hemodinamic criteria: mean pulmonary arterial pressure (mPAP) of 25 mm Hg or more, mean pulmonary arterial wedge pressure (PAWP) or left ventricular end-diastolic pressure (PVEDP) of 15 mm Hg or less, pulmonary vascular resistance (PVR) of 3 Woods.\n\nPatients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension diagnosed before 1st March 2018 (prevalent cases) who:\n\n* are aged \\> 3 months at the time of enrollment\n* fulfill the following hemodinamic criteria: mean pulmonary arterial pressure (mPAP) of 25 mm Hg or more, mean pulmonary arterial wedge pressure (PAWP) or left ventricular end-diastolic pressure (PVEDP) of 15 mm Hg or less, pulmonary vascular resistance (PVR) of 3 Woods","3 Months",{"count":188,"type":20},"The BNP-PL is a multicenter, observational study in which patients are prospectively followed in order to investigate clinical course and management of pulmonary hypertension in Poland.\n\nAll patients diagnosed with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension confirmed in right heart catheterization, will be eligible to participate in the study.",[24,191],[437,115,191,438,439,440],"Pulmonary Hypertension,","Registry","Data Base","Polish patients","2019-05-20",{"date":443,"type":38},"2019-05-22",{"date":445,"type":38},"2018-03-01",{"date":447,"type":20},"2028-02-28",{"name":449,"class":45},"Polish Cardiology Association"]